The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | Low-dose gemcitabine for advanced CTCL
Chalid Assaf, MD, PhD, Helios Klinikum Krefeld, Krefeld, Germany, discusses the clinical outcomes of patients with advanced-stage cutaneous (CTCL) lymphoma who are treated with low-dose gemcitabine. Dr Assaf describes how high-doses are associated with severe side effects, often resulting in discontinuation, leading to investigations into the efficacy of low-dose gemcitabine. Dr Assaf reports that low-dose gemcitabine has been shown to achieve a similar response rate to high-dose gemcitabine, and is also able to achieve similar or even longer durations of response. Dr Assaf also comments on potential benefits of using low-dose gemcitabine in combination with mogamulizumab or brentuximab vedotin. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
